Cargando…

Effectiveness study of atropine for progressive myopia in Europeans

PURPOSE: Randomized controlled trials have shown the efficacy of atropine for progressive myopia, and this treatment has become the preferred pattern for this condition in Taiwan. This study explores the effectiveness of atropine 0.5% treatment for progressive high myopia and adherence to therapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Polling, J R, Kok, R G W, Tideman, J W L, Meskat, B, Klaver, C C W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941076/
https://www.ncbi.nlm.nih.gov/pubmed/27101751
http://dx.doi.org/10.1038/eye.2016.78
_version_ 1782442243368419328
author Polling, J R
Kok, R G W
Tideman, J W L
Meskat, B
Klaver, C C W
author_facet Polling, J R
Kok, R G W
Tideman, J W L
Meskat, B
Klaver, C C W
author_sort Polling, J R
collection PubMed
description PURPOSE: Randomized controlled trials have shown the efficacy of atropine for progressive myopia, and this treatment has become the preferred pattern for this condition in Taiwan. This study explores the effectiveness of atropine 0.5% treatment for progressive high myopia and adherence to therapy in a non-Asian country. METHODS: An effectiveness study was performed in Rotterdam, the Netherlands. Overall 77 children (mean age 10.3 years±2.3), of European (n=53), Asian (n=18), and African (n=6) descent with progressive myopia were prescribed atropine 0.5% eye drops daily. Both parents and children filled in a questionnaire regarding adverse events and adherence to therapy. A standardized eye examination including cycloplegic refraction and axial length was performed at baseline and 1, 4, and 12 months after initiation of therapy. RESULTS: Mean spherical equivalent at baseline was −6.6D (±3.3). The majority (60/77, 78%) of children adhered to atropine treatment for 12 months; 11 of the 17 children who discontinued therapy did so within 1 month after the start of therapy. The most prominent reported adverse events were photophobia (72%), followed by reading problems (38%), and headaches (22%). The progression rate of spherical equivalent before treatment (−1.0D/year±0.7) diminished substantially during treatment (−0.1D/year±0.7) compared to those who ceased therapy (−0.5D/year±0.6; P=0.03). CONCLUSIONS: Despite the relatively high occurrence of adverse events, our study shows that atropine can be an effective and sustainable treatment for progressive high myopia in Europeans.
format Online
Article
Text
id pubmed-4941076
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-49410762016-07-20 Effectiveness study of atropine for progressive myopia in Europeans Polling, J R Kok, R G W Tideman, J W L Meskat, B Klaver, C C W Eye (Lond) Clinical Study PURPOSE: Randomized controlled trials have shown the efficacy of atropine for progressive myopia, and this treatment has become the preferred pattern for this condition in Taiwan. This study explores the effectiveness of atropine 0.5% treatment for progressive high myopia and adherence to therapy in a non-Asian country. METHODS: An effectiveness study was performed in Rotterdam, the Netherlands. Overall 77 children (mean age 10.3 years±2.3), of European (n=53), Asian (n=18), and African (n=6) descent with progressive myopia were prescribed atropine 0.5% eye drops daily. Both parents and children filled in a questionnaire regarding adverse events and adherence to therapy. A standardized eye examination including cycloplegic refraction and axial length was performed at baseline and 1, 4, and 12 months after initiation of therapy. RESULTS: Mean spherical equivalent at baseline was −6.6D (±3.3). The majority (60/77, 78%) of children adhered to atropine treatment for 12 months; 11 of the 17 children who discontinued therapy did so within 1 month after the start of therapy. The most prominent reported adverse events were photophobia (72%), followed by reading problems (38%), and headaches (22%). The progression rate of spherical equivalent before treatment (−1.0D/year±0.7) diminished substantially during treatment (−0.1D/year±0.7) compared to those who ceased therapy (−0.5D/year±0.6; P=0.03). CONCLUSIONS: Despite the relatively high occurrence of adverse events, our study shows that atropine can be an effective and sustainable treatment for progressive high myopia in Europeans. Nature Publishing Group 2016-07 2016-04-22 /pmc/articles/PMC4941076/ /pubmed/27101751 http://dx.doi.org/10.1038/eye.2016.78 Text en Copyright © 2016 Royal College of Ophthalmologists http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Clinical Study
Polling, J R
Kok, R G W
Tideman, J W L
Meskat, B
Klaver, C C W
Effectiveness study of atropine for progressive myopia in Europeans
title Effectiveness study of atropine for progressive myopia in Europeans
title_full Effectiveness study of atropine for progressive myopia in Europeans
title_fullStr Effectiveness study of atropine for progressive myopia in Europeans
title_full_unstemmed Effectiveness study of atropine for progressive myopia in Europeans
title_short Effectiveness study of atropine for progressive myopia in Europeans
title_sort effectiveness study of atropine for progressive myopia in europeans
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941076/
https://www.ncbi.nlm.nih.gov/pubmed/27101751
http://dx.doi.org/10.1038/eye.2016.78
work_keys_str_mv AT pollingjr effectivenessstudyofatropineforprogressivemyopiaineuropeans
AT kokrgw effectivenessstudyofatropineforprogressivemyopiaineuropeans
AT tidemanjwl effectivenessstudyofatropineforprogressivemyopiaineuropeans
AT meskatb effectivenessstudyofatropineforprogressivemyopiaineuropeans
AT klaverccw effectivenessstudyofatropineforprogressivemyopiaineuropeans